Because of DDX3’s characterised roles in several cancers, playing a dual role in cancer progression because of both its oncogenic as well as tumour suppressive activities, DDX3 has emerged as a promising target in cancer therapy (Bol et al., 2015b; Heerma van Voss et al., 2017; He et al., 2018; Lin, 2019; Kukhanova et al., 2020). Here, DDX3X is linked to neoplasm.